| http://dbpedia.org/ontology/abstract
|
Racotumomab (nombre comercial Vaxira®) e … Racotumomab (nombre comercial Vaxira®) es una vacuna terapéutica contra el cáncer destinada al tratamiento de tumores sólidos, desarrollada por Recombio, un consorcio público-privado integrado por instituciones de distintos países, en particular por el Centro de Inmunología Molecular de La Habana, Cuba e investigadores de la Universidad de Buenos Aires y la Universidad Nacional de Quilmes, ambas de Argentina. Induce al sistema inmunológico del paciente a generar una respuesta contra un blanco molecular específico del cáncer, con el fin de controlar el crecimiento del tumor, retrasar el avance de la enfermedad y consiguientemente aumentar la sobrevida del paciente. Racotumomab estimula una respuesta inmune contra el antígeno tumoral N-glicolil GM3 (NGcGM3), un tipo de gangliósido presente en la superficie de células cancerosas de pulmón y mama, melanoma y tumores pediátricos neuroectodérmicos. Racotumomab completó con éxito un ensayo clínico de prueba de concepto en cáncer pulmonar de células no pequeñas (CPCNP o NSCLC, por sus siglas en inglés). Actualmente se está llevando a cabo un ensayo clínico confirmatorio en un estudio multinacional para la misma indicación.o multinacional para la misma indicación.
, Racotumomab (trade name Vaxira) is a thera … Racotumomab (trade name Vaxira) is a therapeutic cancer vaccine for the treatment of solid tumors that is currently under clinical development by Recombio, an international public-private consortium with the participation of the Center of Molecular Immunology at Havana, Cuba (CIM) and researchers from Buenos Aires University and National University of Quilmes in Argentina. It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival. Racotumomab triggers an immune response against the tumor antigen N-glycolyl (NGc) GM3 (NGcGM3), a type of ganglioside present on the cell surface of malignant cells from lung and breast, melanoma, as well as neuroectodermal pediatric tumors. Racotumomab has successfully completed a proof-of concept clinical trial in advanced non-small cell lung cancer (NSCLC) and is currently being tested in a large, multinational study for the same indication.ltinational study for the same indication.
|
| http://dbpedia.org/ontology/alternativeName
|
Vaxira
|
| http://dbpedia.org/ontology/casNumber
|
946832-34-4
|
| http://dbpedia.org/ontology/fdaUniiCode
|
52G405U1E5
|
| http://dbpedia.org/ontology/wikiPageID
|
33058007
|
| http://dbpedia.org/ontology/wikiPageLength
|
9497
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1044616454
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Buenos_Aires_University +
, http://dbpedia.org/resource/Havana +
, http://dbpedia.org/resource/GM3 +
, http://dbpedia.org/resource/Anti-idiotypic +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies +
, http://dbpedia.org/resource/Cuba +
, http://dbpedia.org/resource/Argentina +
, http://dbpedia.org/resource/Common_Toxicity_Criteria +
, http://dbpedia.org/resource/Monoclonal_antibody +
, http://dbpedia.org/resource/Center_of_Molecular_Immunology +
, http://dbpedia.org/resource/National_University_of_Quilmes +
, http://dbpedia.org/resource/Lung_cancer +
, http://dbpedia.org/resource/Alum +
, http://dbpedia.org/resource/Ganglioside +
, http://dbpedia.org/resource/Cancer_vaccine +
|
| http://dbpedia.org/property/atcPrefix
|
none
|
| http://dbpedia.org/property/c
|
6476
|
| http://dbpedia.org/property/casNumber
|
946832
|
| http://dbpedia.org/property/chemspiderid
|
none
|
| http://dbpedia.org/property/h
|
9922
|
| http://dbpedia.org/property/mabType
|
mab
|
| http://dbpedia.org/property/n
|
1712
|
| http://dbpedia.org/property/o
|
2048
|
| http://dbpedia.org/property/s
|
50
|
| http://dbpedia.org/property/source
|
o
|
| http://dbpedia.org/property/target
|
NGNA ganglioside
|
| http://dbpedia.org/property/tradename
|
Vaxira
|
| http://dbpedia.org/property/type
|
mab
|
| http://dbpedia.org/property/unii
|
52
|
| http://dbpedia.org/property/verifiedfields
|
changed
|
| http://dbpedia.org/property/verifiedrevid
|
464379504
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Chemspidercite +
, http://dbpedia.org/resource/Template:Monoclonals_for_tumors +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Drugbankcite +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Monoclonal_antibodies +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Vaccine +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Racotumomab?oldid=1044616454&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Racotumomab +
|
| owl:sameAs |
http://rdf.freebase.com/ns/m.0h55rx4 +
, http://yago-knowledge.org/resource/Racotumomab +
, http://es.dbpedia.org/resource/Racotumomab +
, http://dbpedia.org/resource/Racotumomab +
, https://global.dbpedia.org/id/4tP7X +
, http://www.wikidata.org/entity/Q7279820 +
|
| rdf:type |
http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/ontology/MonoclonalAntibody +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/Part113809207 +
, http://dbpedia.org/class/yago/Relation100031921 +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/MonoclonalAntibody115029781 +
, http://dbpedia.org/class/yago/WikicatMonoclonalAntibodies +
, http://dbpedia.org/class/yago/Molecule114682133 +
, http://dbpedia.org/class/yago/Unit109465459 +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/Thing100002452 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/Protein114728724 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/class/yago/Macromolecule114944888 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/class/yago/Antibody115027189 +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
|
| rdfs:comment |
Racotumomab (nombre comercial Vaxira®) e … Racotumomab (nombre comercial Vaxira®) es una vacuna terapéutica contra el cáncer destinada al tratamiento de tumores sólidos, desarrollada por Recombio, un consorcio público-privado integrado por instituciones de distintos países, en particular por el Centro de Inmunología Molecular de La Habana, Cuba e investigadores de la Universidad de Buenos Aires y la Universidad Nacional de Quilmes, ambas de Argentina. Induce al sistema inmunológico del paciente a generar una respuesta contra un blanco molecular específico del cáncer, con el fin de controlar el crecimiento del tumor, retrasar el avance de la enfermedad y consiguientemente aumentar la sobrevida del paciente.emente aumentar la sobrevida del paciente.
, Racotumomab (trade name Vaxira) is a thera … Racotumomab (trade name Vaxira) is a therapeutic cancer vaccine for the treatment of solid tumors that is currently under clinical development by Recombio, an international public-private consortium with the participation of the Center of Molecular Immunology at Havana, Cuba (CIM) and researchers from Buenos Aires University and National University of Quilmes in Argentina. It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.nd ultimately increasing patient survival.
|
| rdfs:label |
Racotumomab
|
